QTTB
Q32 Bio Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.79
+3.59%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$7.52
From 52W high−63.56%
Volume609901.00
Market cap$231.90M
P/E (TTM)2.8x
P/S (TTM)4.3x
Div yield—
Key dataOct 19, 2026
Open
$7.52
From 52W high
−63.56%
Volume
609901.00
Market cap
$231.90M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
3.8x
P/E (TTM)
2.8x
RSI (14)
31.8
MomentumView details →
1D Return
+3.59%
YTD Return
+134.33%
SummaryUpdated Jun 1, 2026
Q32 Bio Inc. (NASDAQ:QTTB) is a clinical-stage biotechnology company founded in 2017 and headquartered in Waltham, Massachusetts. Originally incorporated as AdMIRx Inc., the company rebranded to Q32 Bio in April 2020 and went public in March 2018. The company focuses on developing innovative biologic therapeutics designed to restore healthy immune balance in patients suffering from autoimmune and inflammatory diseases caused by pathological immune dysfunction.
Similar companies
Latest newsMore news →
Q32 Bio Inc. hired José Trevejo as chief medical officer.10d agoQ32 Bio announced that additional 36-week results and initial 16-week off-drug findings from Part B of the SIGNAL-AA Phase 2a trial of bempikibart in severe or very severe alopecia areata will be presented at the EADV Congress in Vienna, September 30–October 3, 2026.28d agoQ32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata, supporting further development and a planned registration-directed program in the first half of 2027.98d ago